{"id":54492,"date":"2025-11-18T23:29:38","date_gmt":"2025-11-18T17:59:38","guid":{"rendered":"https:\/\/matribhumisamachar.com\/en\/2025\/11\/18\/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors\/"},"modified":"2025-11-18T23:29:38","modified_gmt":"2025-11-18T17:59:38","slug":"lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors","status":"publish","type":"post","link":"https:\/\/matribhumisamachar.com\/en\/2025\/11\/18\/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors\/","title":{"rendered":"Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors"},"content":{"rendered":"<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/api.newsfilecorp.com\/newsinfo\/275016\/511\" width=\"2\" height=\"2\"><\/p>\n<p>Burlington, Massachusetts&#8211;(Newsfile Corp. &#8211; November 18, 2025) &#8211; Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and      inflammatory disorders, today announced a strategic investment from Sanofi Ventures, the venture arm of global healthcare leader Sanofi, and funding from existing investors ARCH Ventures, 5AM      Ventures, and Atlas Venture. The new funds bring the total raised to $112 million and support an ongoing Phase 1 study in Rheumatoid Arthritis (RA) designed to evaluate LFD-200, an ADC      delivering a potent glucocorticoid (GC) directly to immune cells. It also provides for Chemistry Manufacturing and Controls (CMC) preparations to ensure that Phase 2 clinical supply is      available without incurring an unnecessary delay. As part of the investment, Christopher Gagliardi, Ph.D., Principal at Sanofi Ventures, will join as an observer on Lifordi&#8217;s Board of      Directors.    <\/p>\n<p>      To view the full announcement, including downloadable images, bios, and more, <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/xEq3xFzALL\">click      here<\/a>.    <\/p>\n<p>      <b>Key Takeaways:<\/b>    <\/p>\n<ul>\n<li>New strategic investment from Sanofi Ventures, and funding from existing investors ARCH Ventures, 5AM Ventures, and Atlas Venture      <\/li>\n<li>Funds support an ongoing Phase 1 study to evaluate LFD-200, and provides for CMC preparations to ensure Phase 2 clinical supply      <\/li>\n<li>Phase 1 study of LFD-200 in RA is progressing as planned, with initial data from healthy participants in the coming months      <\/li>\n<\/ul>\n<p>      <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/7n2WoT0gWN\"><img decoding=\"async\" src=\"https:\/\/images.newsfilecorp.com\/files\/7294\/275016_figure1_550.jpg\" alt=\"Cannot view this image? Visit: https:\/\/images.newsfilecorp.com\/files\/7294\/275016_figure1_550.jpg\"><\/a>    <\/p>\n<p>      <i>Click image above to view full announcement.<\/i>    <\/p>\n<hr>\n<p>      <strong>About Lifordi<\/strong><br \/>      Lifordi Immunotherapeutics, Inc. is a clinical-stage biotechnology company leading the way by leveraging the success of antibody-drug conjugates (ADCs) to develop treatments for autoimmune and      inflammatory disorders. The Company&#8217;s lead ADC, LFD-200, is in a Phase 1 clinical trial. Preclinical studies demonstrated efficacy in multiple disease models by targeting myeloid and lymphoid      cells using a highly internalized cell surface membrane protein (VISTA). Lifordi has also applied its novel drug delivery platform to other diverse payloads, such as small molecules, antisense      oligonucleotides (ASOs) and siRNA. As experienced drug developers in immunology and inflammatory diseases, together with expert clinical advisors, a strong partnering track record, and funding      from ARCH Venture Partners, 5AM Ventures, and Atlas Venture, Lifordi is committed to changing how immune and inflammatory diseases are treated. For more information, please visit <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/ej7LetDbBy\">www.lifordi.com<\/a>.    <\/p>\n<p>      <strong>About Sanofi Ventures<\/strong>\u00a0<br \/>Sanofi Ventures is the corporate venture capital arm of Sanofi, investing globally in early-stage biotech and digital health companies aligned with      Sanofi&#8217;s mission to chase the miracles of science. Areas of focus include immunology, oncology, rare diseases, vaccines, and digital innovation.    <\/p>\n<div>\n<p>      <b>Contacts:<\/b>    <\/p>\n<p>      Theresa McNeely<br \/>      (508) 523-9511<br \/>      <a href=\"mailto:tmcneely@lifordi.com\">tmcneely@lifordi.com<\/a>    <\/p>\n<\/div>\n<p>      Source: <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/87251Tap71\">Lifordi<\/a>    <\/p>\n<p>      To view the source version of this press release, please visit <a href=\"https:\/\/api.newsfilecorp.com\/redirect\/y42ExSpmnY\">https:\/\/www.newsfilecorp.com\/release\/275016<\/a>    <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Burlington, Massachusetts&#8211;(Newsfile Corp. &#8211; November 18, 2025) &#8211; Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, today announced a strategic investment from Sanofi Ventures, the venture arm of global healthcare leader Sanofi, and funding from existing investors ARCH Ventures, 5AM Ventures, and Atlas Venture. &hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[130],"tags":[],"class_list":["post-54492","post","type-post","status-publish","format-standard","","category-international"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.8.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors - Matribhumi Samachar English<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/matribhumisamachar.com\/en\/2025\/11\/18\/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors - Matribhumi Samachar English\" \/>\n<meta property=\"og:description\" content=\"Burlington, Massachusetts&#8211;(Newsfile Corp. &#8211; November 18, 2025) &#8211; Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, today announced a strategic investment from Sanofi Ventures, the venture arm of global healthcare leader Sanofi, and funding from existing investors ARCH Ventures, 5AM Ventures, and Atlas Venture. &hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/matribhumisamachar.com\/en\/2025\/11\/18\/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors\/\" \/>\n<meta property=\"og:site_name\" content=\"Matribhumi Samachar English\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-18T17:59:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/api.newsfilecorp.com\/newsinfo\/275016\/511\" \/>\n<meta name=\"author\" content=\"Saransh Kanaujia\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Saransh Kanaujia\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2025\/11\/18\/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors\/\",\"url\":\"https:\/\/matribhumisamachar.com\/en\/2025\/11\/18\/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors\/\",\"name\":\"Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors - Matribhumi Samachar English\",\"isPartOf\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#website\"},\"datePublished\":\"2025-11-18T17:59:38+00:00\",\"dateModified\":\"2025-11-18T17:59:38+00:00\",\"author\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1\"},\"breadcrumb\":{\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2025\/11\/18\/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/matribhumisamachar.com\/en\/2025\/11\/18\/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/2025\/11\/18\/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/matribhumisamachar.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#website\",\"url\":\"https:\/\/matribhumisamachar.com\/en\/\",\"name\":\"Matribhumi Samachar English\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/matribhumisamachar.com\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1\",\"name\":\"Saransh Kanaujia\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g\",\"caption\":\"Saransh Kanaujia\"},\"description\":\"Saransh Kanaujia is currently editor of Matribhumi Samachar Group. He earlier worked with Hindusthan Samachar News Agency. He is also associated with many organizations.\",\"sameAs\":[\"https:\/\/matribhumisamachar.com\/en\"],\"url\":\"https:\/\/matribhumisamachar.com\/en\/author\/matribhumisamachar\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors - Matribhumi Samachar English","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/matribhumisamachar.com\/en\/2025\/11\/18\/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors\/","og_locale":"en_US","og_type":"article","og_title":"Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors - Matribhumi Samachar English","og_description":"Burlington, Massachusetts&#8211;(Newsfile Corp. &#8211; November 18, 2025) &#8211; Lifordi Immunotherapeutics, Inc., a clinical-stage biotech company developing antibody-drug conjugates (ADCs) for the treatment of autoimmune and inflammatory disorders, today announced a strategic investment from Sanofi Ventures, the venture arm of global healthcare leader Sanofi, and funding from existing investors ARCH Ventures, 5AM Ventures, and Atlas Venture. &hellip;","og_url":"https:\/\/matribhumisamachar.com\/en\/2025\/11\/18\/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors\/","og_site_name":"Matribhumi Samachar English","article_published_time":"2025-11-18T17:59:38+00:00","og_image":[{"url":"https:\/\/api.newsfilecorp.com\/newsinfo\/275016\/511"}],"author":"Saransh Kanaujia","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Saransh Kanaujia","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/matribhumisamachar.com\/en\/2025\/11\/18\/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors\/","url":"https:\/\/matribhumisamachar.com\/en\/2025\/11\/18\/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors\/","name":"Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors - Matribhumi Samachar English","isPartOf":{"@id":"https:\/\/matribhumisamachar.com\/en\/#website"},"datePublished":"2025-11-18T17:59:38+00:00","dateModified":"2025-11-18T17:59:38+00:00","author":{"@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1"},"breadcrumb":{"@id":"https:\/\/matribhumisamachar.com\/en\/2025\/11\/18\/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/matribhumisamachar.com\/en\/2025\/11\/18\/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/matribhumisamachar.com\/en\/2025\/11\/18\/lifordi-immunotherapeutics-secures-strategic-investment-from-sanofi-ventures-and-additional-capital-from-existing-investors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/matribhumisamachar.com\/en\/"},{"@type":"ListItem","position":2,"name":"Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors"}]},{"@type":"WebSite","@id":"https:\/\/matribhumisamachar.com\/en\/#website","url":"https:\/\/matribhumisamachar.com\/en\/","name":"Matribhumi Samachar English","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/matribhumisamachar.com\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/0a61403f4baf9627e92218b53a1e65f1","name":"Saransh Kanaujia","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/matribhumisamachar.com\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/45a8b03a1b1bb8255014f5e62f9cfea0eb8a9f7a6a604f9879038df08da23cea?s=96&d=mm&r=g","caption":"Saransh Kanaujia"},"description":"Saransh Kanaujia is currently editor of Matribhumi Samachar Group. He earlier worked with Hindusthan Samachar News Agency. He is also associated with many organizations.","sameAs":["https:\/\/matribhumisamachar.com\/en"],"url":"https:\/\/matribhumisamachar.com\/en\/author\/matribhumisamachar\/"}]}},"_links":{"self":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/54492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/comments?post=54492"}],"version-history":[{"count":0,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/posts\/54492\/revisions"}],"wp:attachment":[{"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/media?parent=54492"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/categories?post=54492"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/matribhumisamachar.com\/en\/wp-json\/wp\/v2\/tags?post=54492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}